top of page

Rubix LS enters into an agreement to support infectious disease data research

July 17, 2019 – Lawrence, MA – Today, Rubix LS is announcing that they’re expanding their virtual clinical trial and disease intelligence platform that will include the nations: Morocco, Kenya, Indonesia and Brazil as part of a wider United Nations,, health program for understanding commonalities of disease trends and creating the pathways to access for underrepresented patient populations.

Slated to commence at the end of 2019, it is hopeful with all of the travels of people traveling back home, the ability to capture much more robust data will enable faster delivery and collaboration of genealogical genetic mutations that can occur over a generational period. Initially targeting the susceptibility of certain infectious diseases, the data will provide a platform of how cellular malleability is unique within each given cultural subset.

Founder & CEO, Reginald Swift, shared “Unlocking the power of culture not only powers deeper genomic intelligence but enables better calibration of how we understand why certain deadly infectious diseases behave the way they do when they jump oceans and affect other people differently”

Engineering Director, Americo Diaz, also harmonizes on the fact that “To really understand how we can help enable the creation of an alternative to ‘one-size-fits-all’ therapeutic remedies will increase our chances to get to cures faster than ever before”

About Rubix LS:

Founded in 2016, Rubix LS has utilized the power of research and development to create offensive and defensive combination innovations that close the gaps of therapeutics, diagnostics, intelligence, and processes to make effective outcomes for people who need it and are underrepresented. With a mix of scientists, business strategists, researchers, engineers, and expert doctors, Rubix LS functions as both innovators and service providers, that blend of methodologies to greatly increase effective patient outcomes.

bottom of page